Myelodysplastic syndromes (MDS) cause atypical bone marrow cells and low blood counts. This can lead to fatigue, shortness of breath, infections, bruising, and bleeding. Myelodysplastic syndromes (MDS ...

Key considerations for appropriate MDS treatment selection are discussed by expert panelists. Ryan Haumschild, PharmD, MS, MBA: Dr Weaver, I’m curious about your thoughts. I’m hearing that there are ...

Fatigue is one of the most common symptoms in myelodysplastic syndromes (MDS), and severe fatigue has been linked with less favorable mortality outcomes. Low blood cell counts (cytopenias) can drive ...

—Do secondary mutations explain why patients with AML with a history of myelodysplasia-related changes and the NPM1 mutation have outcomes that are inferior to those in patients with normal ...

Infection is the leading cause of death in LR-MDS patients, responsible for 24.6% of deaths within a year of diagnosis. Key risk factors for infection include intermediate or higher IPSS-R risk, ...

Reblozyl for anemia in patients with an MDS subset demonstrated positive effects, compared with previous treatments, according to an MDS expert. Treatment with Reblozyl (luspatercept-aamt) was ...

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS. Reblozyl (luspatercept) has become the new standard ...